PMID: 18729014Aug 30, 2008Paper

Treating acute ischemic stroke

Current Opinion in Drug Discovery & Development
Marc Fisher, Birgul Bastan

Abstract

Acute ischemic stroke (AIS) is a common disorder that has only one associated approved therapy: intravenous tissue plasminogen activator (iv t-PA). A limiting factor to the use of iv t-PA is that it must be initiated within 3 h of stroke onset. Efforts to expand the therapeutic time window are underway and include image evaluation of the ischemic penumbra to target those patients who are most appropriate for treatment. Intra-arterial t-PA is also used only in some treatment centers despite convincing proof of efficacy of this therapy. Devices to restore perfusion that have been approved in the US for recanalization exist, but these are not approved for use in stroke therapy. Many neuroprotective drugs have been evaluated as potential acute stroke therapies, but none have shown efficacy, hence the future of neuroprotection as a strategy for acute ischemic stroke therapy remains uncertain.

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Related Papers

Expert Review of Neurotherapeutics
Vasantha PadmaMajaz Moonis
Current Atherosclerosis Reports
Neelofer Shafi, Joshua M Levine
International Journal of Stroke : Official Journal of the International Stroke Society
Yilong WangITAIS-II investigators
© 2022 Meta ULC. All rights reserved